Loading
A phase 1/2 trial of Lenalidomide, Dexamethasone in multiple myeloma, run by Starton Therapeutics, Inc, now recruiting.
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) is a phase 1/2 interventional study registered as NCT06087653 by Starton Therapeutics, Inc, with 24 participants planned, started 2023-10-02 and due to reach its primary completion in 2027-05-31. Interventions recorded: Lenalidomide, Lenalidomide 25 MG Oral Capsule. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Lenalidomide, Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Lenalidomide, Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Lenalidomide, Dexamethasone, Multiple myeloma.
Shares Lenalidomide, Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation).